Cantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a report issued on Monday, Benzinga reports.

AFMD has been the topic of several other reports. Wells Fargo & Company dropped their price objective on Affimed from $30.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday. HC Wainwright upped their price objective on shares of Affimed to $10.00 and gave the stock a "buy" rating in a research report on Monday. Finally, StockNews.com began coverage on shares of Affimed in a research note on Tuesday, January 2nd. They issued a "sell" rating for the company. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Affimed presently has an average rating of "Moderate Buy" and a consensus target price of $45.00.

Affimed Stock Up 19.8 %

AFMD traded up $1.05 during midday trading on Monday, reaching $6.35. 228,194 shares of the company were exchanged, compared to its average volume of 94,291. The company has a market cap of $94.81 million, a price-to-earnings ratio of -0.76 and a beta of 2.05. Affimed has a one year low of $2.23 and a one year high of $11.10. The company's fifty day moving average price is $5.45 and its 200 day moving average price is $4.90. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.67 and a current ratio of 3.70.

Institutional Trading of Affimed

Several hedge funds have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in shares of Affimed during the 1st quarter worth $27,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Affimed during the second quarter valued at approximately $31,000. UBS Group AG boosted its position in Affimed by 42.2% during the 1st quarter. UBS Group AG now owns 47,073 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 13,979 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Affimed by 30.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 3,202 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its stake in shares of Affimed by 258.3% in the first quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 6,464 shares during the last quarter. 30.82% of the stock is currently owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.